New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction-ICI-RS 2023.

Anthony J Kanai Basu ChakrabartyMichael WinderHashim HashimAlan WeinPaul Abrams Christopher Henry Fry

Published in: Neurourology and urodynamics (2023)

Several new drug targets were identified, including soluble guanylate cyclase (sGC), the receptor for nitric oxide (NO•), and sGC activators that promotes sGC-mediated cGMP production when sGC is inactivated and unresponsive to NO•.

Keyphrases

nitric oxide
benign prostatic hyperplasia
radical prostatectomy
nitric oxide synthase
hydrogen peroxide
prostate cancer
emergency department
adverse drug
protein kinase